London, UK – 05 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes the announcement by its portfolio company, ProAxsis, which will have its ProteaseTag® technology featured at the 2017 British Thoracic Society Winter Meeting on the 7th and 8th of December.
The first presentation will cover lung patient care: “NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease” by Dr Kelly Moffitt, COO of ProAxsis on the 7thof December. The second presentation will cover the clinical implications of cystic fibrosis: “It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis” by Dr Claire Edmondson, NHLI Imperial College and Royal Brompton Hospital, London on the 8th December.
NetScientific holds a 57% stake on a fully diluted basis in ProAxsis.
The full text of the announcement from ProAxsis can be found below.
# # #
For more information, please contact:
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
ProAxsis to Present at 2017 British Thoracic Society Winter Meeting
Date: December 05, 2017
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at the Queen Elizabeth II Conference Centre, in London. Further details of the abstracts accepted for presentation by the conference review committee are detailed below:
NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease (Poster no. 116).
Presenting author: Dr Kelly Moffitt (ProAxsis Limited)
Session – Infected lung: from bench to bedside
Thursday 7th December
It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis (Poster no. 249).
Presenting author: Dr Claire Edmondson (NHLI Imperial College and Royal Brompton Hospital, London)
Session – Clinical implications of cystic fibrosis
Friday 8th December
Dr David Ribeiro, CEO of ProAxsis, said: “The BTS stated goal is to improve standards of care for people who have respiratory diseases, and the organisation currently has more than 3400 members. Having recently registered a European CE Mark for our rapid neutrophil elastase point-of-care test, NEATstik®, ProAxsis is delighted to be sharing the first real world data for this exciting new product at the BTS meeting.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact email@example.com.
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. Its first immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.